<SEC-DOCUMENT>0000932471-25-000267.txt : 20250131
<SEC-HEADER>0000932471-25-000267.hdr.sgml : 20250131
<ACCEPTANCE-DATETIME>20250131100931
ACCESSION NUMBER:		0000932471-25-000267
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250131

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Travere Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001438533
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				262383102
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87088
		FILM NUMBER:		25576421

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DR
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		888-969-7879

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DR
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Retrophin, Inc.
		DATE OF NAME CHANGE:	20130220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Desert Gateway, Inc.
		DATE OF NAME CHANGE:	20080625

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VANGUARD GROUP INC
		CENTRAL INDEX KEY:			0000102909
		ORGANIZATION NAME:           	
		IRS NUMBER:				231945930
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		100 VANGUARD BLVD
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		6106691000

	MAIL ADDRESS:	
		STREET 1:		PO BOX 2600
		STREET 2:		V26
		CITY:			VALLEY FORGE
		STATE:			PA
		ZIP:			19482-2600
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001104659-20-016391</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000102909</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>7</amendmentNo>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001438533</issuerCik>
<issuerName>Travere Therapeutics Inc</issuerName>
<issuerCusip>89422G107</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>3611 Valley Centre Drive Suite 300</com:street1>
<com:city>San Diego</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>92130</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>The Vanguard Group</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>PA</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>53801</sharedVotingPower>
<soleDispositivePower>6609593</soleDispositivePower>
<sharedDispositivePower>132572</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6742165</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<classPercent>7.75</classPercent>
<typeOfReportingPerson>IA</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Travere Therapeutics Inc</issuerName>
<issuerPrincipalExecutiveOfficeAddress>3611 Valley Centre Drive Suite 300, San Diego, CA, 92130</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>The Vanguard Group</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>100 Vanguard Blvd., Malvern, PA 19355</principalBusinessOfficeOrResidenceAddress>
<citizenship>PA</citizenship>
</item2>
<item3>
<notApplicableFlag>N</notApplicableFlag>
<typeOfPersonFiling>IA</typeOfPersonFiling>
</item3>
<item4>
<amountBeneficiallyOwned>6742165</amountBeneficiallyOwned>
<classPercent>7.75</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>0</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>53801</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>6609593</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>132572</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>N</notApplicableFlag>
<ownershipMoreThan5PercentOnBehalfOfAnotherPerson>The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

No one other person's interest in the securities reported herein is more than 5%.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>The Vanguard Group</reportingPersonName>
<signatureDetails>
<signature>Ashley Grim</signature>
<title>Head of Global Fund Administration</title>
<date>01/31/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
